|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0185117,
umls-concept:C0268141,
umls-concept:C0280100,
umls-concept:C0431085,
umls-concept:C0532362,
umls-concept:C0596402,
umls-concept:C1158557,
umls-concept:C1333232,
umls-concept:C1333359,
umls-concept:C1705470,
umls-concept:C1707520,
umls-concept:C2911684
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2004-8-25
|
|
pubmed:abstractText |
Irofulven is a novel alkylating agent with promising clinical activity, particularly toward ovarian and hormone-refractory prostate cancers. To facilitate additional clinical development, we have aimed to identify biological markers associated with sensitivity to the compound.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/DNA excision repair protein ERCC-5,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Endonucleases,
http://linkedlifedata.com/resource/pubmed/chemical/Nuclear Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Sesquiterpenes,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/irofulven
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5604-13
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15328203-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15328203-Base Sequence,
pubmed-meshheading:15328203-Cell Division,
pubmed-meshheading:15328203-Cell Line, Tumor,
pubmed-meshheading:15328203-Cell Survival,
pubmed-meshheading:15328203-Cells, Cultured,
pubmed-meshheading:15328203-Cockayne Syndrome,
pubmed-meshheading:15328203-DNA, Neoplasm,
pubmed-meshheading:15328203-DNA Primers,
pubmed-meshheading:15328203-DNA Repair,
pubmed-meshheading:15328203-DNA-Binding Proteins,
pubmed-meshheading:15328203-Endonucleases,
pubmed-meshheading:15328203-Humans,
pubmed-meshheading:15328203-Nuclear Proteins,
pubmed-meshheading:15328203-Sesquiterpenes,
pubmed-meshheading:15328203-Transcription, Genetic,
pubmed-meshheading:15328203-Transcription Factors,
pubmed-meshheading:15328203-Xeroderma Pigmentosum
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
|
|
pubmed:affiliation |
Group of Biology and Pharmacogenetics of Human Tumors, Centre National de la Recherche Scientifique, UMR 8113, Institut Gustave-Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
